Financing round · Healthtech
MOYOM Biotech secures undisclosed financing from Cathay Capital fund
The Chinese company is advancing a certified regenerative-aesthetics biomaterial already used by more than 700 clinics in China.
A certified biomaterial with clinic adoption
MOYOM's Aphranel combines calcium hydroxylapatite microspheres with a physically cross-linked gel designed to provide structural support and controlled biodegradation. The product has received China Class III medical-device registration and European MDR certification, and the company says it has entered more than 700 medical-aesthetics clinics in China since launching in May 2025.
Use of funds
Accelerate clinical translation and pursue additional regulatory approvals
Expand into overseas markets
Continue investment in next-generation regenerative biomaterials
Funding history
Financing round · This roundUndisclosed